Infinity Bio: A New Dawn in Immune Mapping
June 24, 2025, 3:37 pm
Infinity Bio, Inc.
Total raised: $8M
In the world of biotechnology, innovation is the lifeblood. Infinity Bio, a rising star based in Baltimore, MD, has just secured $8 million in Series A funding. This infusion of capital is not just a financial boost; it’s a launchpad for a revolution in understanding the immune system.
Founded in 2023, Infinity Bio is on a mission to map immune responses at scale. The company’s flagship technology, the MIPSA platform, is a beacon in the fog of immunology. It offers a detailed view of the antibody reactome, the intricate web of immune responses that can reveal how our bodies fight off diseases. This technology can analyze responses to known human viruses, autoimmunity, and allergens.
The funding round was led by Illumina Ventures, a heavyweight in the biotech investment arena. PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund also joined the fray. This diverse group of investors signals confidence in Infinity Bio’s vision. The company plans to use the funds to expand its commercial footprint and accelerate the development of its MIPSA platform.
Infinity Bio has already established a 9,000 square-foot laboratory in Baltimore. This facility is not just a workspace; it’s a hub of innovation. The company has developed a suite of services, including HuSIGHT, VirSIGHT, AllerSIGHT, and MuSIGHT. Each service is designed to support biomarker discovery, basic and translational research, and therapeutic development. This comprehensive approach positions Infinity Bio as a key player in the biotech landscape.
The company’s ambition doesn’t stop there. Infinity Bio recently acquired the assets of Serimmune, a company that has been providing unbiased antibody reactome services since 2014. This acquisition is a strategic move to broaden Infinity Bio’s service offerings. New services, including EnviroSIGHT, are set to launch in the latter half of 2025. This expansion is a testament to Infinity Bio’s commitment to staying at the forefront of immune profiling technology.
The MIPSA platform is a game changer. It enables high-resolution analysis of the antibody reactome, a critical area for understanding immune responses in both health and disease. The platform’s capacity to process thousands of samples per week makes it invaluable for academic, government, and biopharma customers. This scalability is essential in a field where speed and accuracy can mean the difference between life and death.
The implications of Infinity Bio’s work are profound. In a world where diseases can emerge and spread rapidly, understanding the immune system is more crucial than ever. The insights generated by the MIPSA platform could lead to better diagnostics and targeted therapies. This could transform how we approach diseases, from cancer to autoimmune disorders.
Infinity Bio’s leadership is equally impressive. CEO Joy Nassif is steering the ship with a clear vision. Under her guidance, the company is building a foundation for a new category of immune system intelligence. This intelligence is not just about data; it’s about making that data accessible and actionable.
The scientific community is taking notice. Experts recognize the potential of Infinity Bio’s technology to illuminate the complex interplay between inflammation, immunity, and health. This is not just another biotech company; it’s a pioneer in a field that holds the key to understanding some of humanity’s most pressing health challenges.
As Infinity Bio moves forward, it faces the challenges that come with rapid growth. The biotech landscape is competitive, and the pressure to deliver results is immense. However, with a solid foundation and a clear vision, Infinity Bio is poised to become a leader in antibody reactome profiling.
The future looks bright for Infinity Bio. The $8 million in funding is more than just a financial milestone; it’s a signal of what’s to come. The company is ready to scale, ready to innovate, and ready to make a difference.
In conclusion, Infinity Bio is not just mapping immune responses; it’s charting a course for the future of medicine. With its cutting-edge technology and ambitious plans, the company is set to unlock new layers of immune system data. This could lead to breakthroughs that change lives. As the world watches, Infinity Bio stands at the forefront of a new era in biotechnology. The journey has just begun, and the possibilities are limitless.
Founded in 2023, Infinity Bio is on a mission to map immune responses at scale. The company’s flagship technology, the MIPSA platform, is a beacon in the fog of immunology. It offers a detailed view of the antibody reactome, the intricate web of immune responses that can reveal how our bodies fight off diseases. This technology can analyze responses to known human viruses, autoimmunity, and allergens.
The funding round was led by Illumina Ventures, a heavyweight in the biotech investment arena. PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund also joined the fray. This diverse group of investors signals confidence in Infinity Bio’s vision. The company plans to use the funds to expand its commercial footprint and accelerate the development of its MIPSA platform.
Infinity Bio has already established a 9,000 square-foot laboratory in Baltimore. This facility is not just a workspace; it’s a hub of innovation. The company has developed a suite of services, including HuSIGHT, VirSIGHT, AllerSIGHT, and MuSIGHT. Each service is designed to support biomarker discovery, basic and translational research, and therapeutic development. This comprehensive approach positions Infinity Bio as a key player in the biotech landscape.
The company’s ambition doesn’t stop there. Infinity Bio recently acquired the assets of Serimmune, a company that has been providing unbiased antibody reactome services since 2014. This acquisition is a strategic move to broaden Infinity Bio’s service offerings. New services, including EnviroSIGHT, are set to launch in the latter half of 2025. This expansion is a testament to Infinity Bio’s commitment to staying at the forefront of immune profiling technology.
The MIPSA platform is a game changer. It enables high-resolution analysis of the antibody reactome, a critical area for understanding immune responses in both health and disease. The platform’s capacity to process thousands of samples per week makes it invaluable for academic, government, and biopharma customers. This scalability is essential in a field where speed and accuracy can mean the difference between life and death.
The implications of Infinity Bio’s work are profound. In a world where diseases can emerge and spread rapidly, understanding the immune system is more crucial than ever. The insights generated by the MIPSA platform could lead to better diagnostics and targeted therapies. This could transform how we approach diseases, from cancer to autoimmune disorders.
Infinity Bio’s leadership is equally impressive. CEO Joy Nassif is steering the ship with a clear vision. Under her guidance, the company is building a foundation for a new category of immune system intelligence. This intelligence is not just about data; it’s about making that data accessible and actionable.
The scientific community is taking notice. Experts recognize the potential of Infinity Bio’s technology to illuminate the complex interplay between inflammation, immunity, and health. This is not just another biotech company; it’s a pioneer in a field that holds the key to understanding some of humanity’s most pressing health challenges.
As Infinity Bio moves forward, it faces the challenges that come with rapid growth. The biotech landscape is competitive, and the pressure to deliver results is immense. However, with a solid foundation and a clear vision, Infinity Bio is poised to become a leader in antibody reactome profiling.
The future looks bright for Infinity Bio. The $8 million in funding is more than just a financial milestone; it’s a signal of what’s to come. The company is ready to scale, ready to innovate, and ready to make a difference.
In conclusion, Infinity Bio is not just mapping immune responses; it’s charting a course for the future of medicine. With its cutting-edge technology and ambitious plans, the company is set to unlock new layers of immune system data. This could lead to breakthroughs that change lives. As the world watches, Infinity Bio stands at the forefront of a new era in biotechnology. The journey has just begun, and the possibilities are limitless.